AdvaMed 510(k) study: Study prepared for AdvaMed by Battelle Memorial Institute finds that just 0.16% of the nearly 47,000 devices cleared via 510(k) since 1998 were involved in a Class I recall, the most serious category. The study looked at recall data from January 2005 to May 2010. Of the nearly 3,000 PMAs approved since 1998, 0.85% were subject to a Class I recall. A similar study of FDA recall data was presented by Baker & Daniels attorney Ralph Hall at a recent Institute of Medicine workshop (1"The Gray Sheet" Aug. 2, 2010). "These studies reinforce the fact that the basic structure of the 510(k) process is sound," AdvaMed CEO Stephen Ubl said in a Sept. 15 statement. The data is telling in light of FDA's "sweeping proposed reforms" to the 510(k) program, AdvaMed executive David Nexon said during a Sept. 15 call. "As we look at the [FDA] recommendations, some of them are very constructive," such as more training for reviewers and better guidance, "but some are very troublesome because they would add to the complexity and difficulty of getting products developed or approved," Nexon said
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.
Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.